Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Adenosine Triphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.82 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.82 |
| ▸ | P2RY1 | P47900 | 7/20 | 0.93 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.93 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.93 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.93 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.93 |
| ▸ | SRC | P12931 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.93 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.87 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.86 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.86 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.86 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.86 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.82 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.82 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.82 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL29375927 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| SCHEMBL9171542 | 0.99 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL20550531 | 0.99 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL8979 | 0.99 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL12789528 | 0.99 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL2227081 | 0.99 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| SCHEMBL376008 | 0.99 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL18784961 | 0.99 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Diphosphate SCHEMBL8321453 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL6242713 | 0.99 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275972-B2 | Microorganism producing purine nucleotide and method of producing purine nucleotide using the same | CJ CHEILJEDANG CORPORATION (KR) | 2025-04-15 | — | — | US | disclosed |
| US-20220380821-A1 | MICROORGANISM PRODUCING PURINE NUCLEOTIDE AND METHOD OF PRODUCING PURINE NUCLEOTIDE USING THE SAME | CJ CHEILJEDANG CORPORATION (KR) | 2022-12-01 | — | — | US | disclosed |
| CN-102565356-A | Ammonia (ammonia ion) determination method and ammonia (ammonia ion) diagnosis/determination kit | SUZHOU ANJ BIOTECH CO LTD | 2012-07-11 | — | — | CN | disclosed |
| CN-1679608-A | Compound preparation of inosine, triphosphoadenosine and vitamin C and use thereof | FUKANGREN ORGANISM PHARMACEUTI (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1679924-A | Compound insulin energy mistura preparation and use thereof | FUKANGREN BIO PHARMACEUTICAL S (CN) | 2005-10-12 | — | — | CN | disclosed |
| US-20030166605-A1 | Method of minimizing damage to heart tissue during cardiac surgery and cardiac transplantation | LEUNG EDWARD (US) | 2003-09-04 | — | — | US | disclosed |
| EP-0290496-B2 | USE OF AN ADENOSINE, HYPOXANTHINE AND RIBOSE-CONTAINING SOLUTION FOR IMPROVED PROTECTION OF THE HEART DURING SURGERY | UNIV VIRGINIA (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0290496-B1 | USE OF AN ADENOSINE, HYPOXANTHINE AND RIBOSE-CONTAINING SOLUTION FOR IMPROVED PROTECTION OF THE HEART DURING SURGERY | THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1992-10-28 | — | — | EP | disclosed |
| EP-0290496-A4 | USE OF AN ADENOSINE, HYPOXANTHINE AND RIBOSE-CONTAINING SOLUTION FOR IMPROVED PROTECTION OF THE HEART DURING SURGERY. | UNIV VIRGINIA (US) | 1989-11-29 | — | — | EP | disclosed |
| US-4880783-A | ANTIISCHEMIC AGENTS | UNIVERSITY OF VIRGINIA ALUMNIA PATENTS FOUNDATION (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0290496-A1 | USE OF AN ADENOSINE, HYPOXANTHINE AND RIBOSE-CONTAINING SOLUTION FOR IMPROVED PROTECTION OF THE HEART DURING SURGERY. | UNIV VIRGINIA (US) | 1988-11-17 | — | — | EP | disclosed |
| WO-1988002258-A1 | USE OF AN ADENOSINE, HYPOXANTHINE AND RIBOSE-CONTAINING SOLUTION FOR IMPROVED PROTECTION OF THE HEART DURING SURGERY | THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATI (US) | 1988-04-07 | — | — | WO | disclosed |